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Abstract
Parkinson’s disease (PD) is a chronic neurodegenerative disease characterized by a signifi-
cant loss of dopaminergic neurons within the substantia nigra pars compacta (SNpc) and a
subsequent loss of dopamine (DA) within the striatum. Despite advances in the develop-
ment of pharmacological therapies that are effective at alleviating the symptoms of PD, the
search for therapeutic treatments that halt or slow the underlying nigral degeneration re-
mains a particular challenge. Activin A, a member of the transforming growth factor β super-
family, has been shown to play a role in the neuroprotection of midbrain neurons against 6-
hydroxydopamine (6-OHDA) in vitro, suggesting that activin A may offer similar neuropro-
tective effects in in vivomodels of PD. Using robust stereological methods, we found that
intrastriatal injections of 6-OHDA results in a significant loss of both TH positive and NeuN
positive populations in the SNpc at 1, 2, and 3 weeks post-lesioning in drug naïve mice. Ex-
ogenous application of activin A for 7 days, beginning the day prior to 6-OHDA administra-
tion, resulted in a significant survival of both dopaminergic and total neuron numbers in the
SNpc against 6-OHDA-induced toxicity. However, we found no corresponding protection of
striatal DA or dopamine transporter (DAT) expression levels in animals receiving activin A
compared to vehicle controls. These results provide the first evidence that activin A exerts
potent neuroprotection in a mouse model of PD, however this neuroprotection may be local-
ized to the midbrain.
Introduction
Parkinson’s disease (PD) is a chronic neurodegenerative disease characterized by significant
loss of dopaminergic neurons within the substantia nigra pars compacta (SNpc) and a subse-
quent loss of dopamine (DA) within the striatum. While the use of levodopa (L-Dopa) has pro-
vided considerable benefits in the treatment of the motor symptoms, one of the remaining
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challenges in PD research is the search for therapeutic treatments that address the underlying
nigral degeneration. One of the most promising avenues in recent years has been the adminis-
tration of growth factors to promote the survival of remaining midbrain neurons and stimulate
the growth of process from immature neurons.
While their exact mechanisms of action still remain to be fully elucidated, growth factors
have been demonstrated to act as neuroprotective molecules against cytotoxic cell damage via
upregulation of calcium buffering proteins, antioxidant enzymes, and anti-apoptotic factors [1]
suggesting that their administration either prior to, or after a neurotoxic insult may provide
protection to vulnerable neuronal populations. These properties make growth factors ideal as
therapeutic targets as PD.
Activin A is a member of the transforming growth factor (TGF)-β superfamily, which are
known to be involved in development, inflammation and repair of tissues and organs. A num-
ber of studies have shown that activin A may play a particular role in the neuroprotection of
CNS regions and functions following injury. In situ hybridization studies have demonstrated
an increase in activin A mRNA expression in neurons near the site of CNS injury following
lesioning with the excitotoxin kainic acid (KA) [2] as well as increased expression up to 7 days
after unilateral hypoxic-ischemic injury in the rat brain [3].
The neuroprotective potential of activin A was first investigated in the KA model of acute
brain injury, with the administration of exogenous recombinant activin A exerting potent neu-
roprotection against KA-induced excitotoxicity in the hippocampus [4]. Interestingly, further
investigations revealed that in the presence of the activin-binding protein follistatin, the neuro-
protective action of fibroblast growth factor 2 (FGF-2; a well characterized neuroprotective
molecule) was lost in the KA model, suggesting that activin A may be an essential mediator for
neuroprotection in degenerative models [4].
In addition to its known neuroprotective effects in the hippocampus, activin A has been
shown to exert neuroprotective effects in midbrain neurons in vitro, with the addition of re-
combinant activin A to dopaminergic neurons isolated from rat mesencephalon floor resulting
in more tyrosine hydroxylase (TH) positive cells after 8 days in culture compared to untreated
controls, representing a 2.5 fold increase in survival of dopaminergic neurons. Furthermore,
the presence of activin A significantly reduced MPP+-induced cell loss when administered
prior to exposure with the neurotoxin [5]. More recently, addition of activin A to human
SH-SY5Y neuroblastoma cells attenuated both degeneration induced by serum withdrawal and
6-OHDA administration, with this neuroprotection inhibited by follistatin [6]. The ability of
activin A to provide significant neuroprotection in vitro against established toxins used to
model the pathological events of human PD in animals, suggests that activin A may provide a
novel target for halting midbrain degeneration. Our study provides the first evidence that exog-
enous application of activin A prior to 6-OHDA administration provides significant protection
of midbrain neurons from degeneration in vivo.
Materials and Methods
Animals
C57BL/6 male mice aged 12 weeks were obtained from Australian BioResources (Mona Vale,
Australia). Mice were housed at a maximum five mice per cage, until the study began, at which
time mice were housed individually. Mice were kept on a 12-hour light/dark cycle with access
to food and water ad libitum. All animal experiments were performed with the approval of the
Garvan Institute and St. Vincent’s Hospital Animal Ethics Committee under approval number
12/36, in accordance with National Health and Medical Research Council animal experimenta-
tion guidelines and the Australian Code of Practice for the Care and Use of Animals for
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Scientific Purposes (2004). All surgery was performed under ketamine/xylazil anesthesia, and
all efforts were made to minimize suffering. For all immunohistochemical experiments animals
were anaesthetized via a ketamine/xylazil mixture before cardiac perfusion with 4% parafor-
maldehyde. For all rapid euthanasia and tissue collection animals were anaesthetized via iso-
fluorane followed by cervical dislocation.
Osmotic micro-pump implantation
For all neuroprotection studies animals were anaesthetized with a mixture of ketamine (8.7
mg/ml; Mavlab, Slack Creek, QLD) and xylazil (2 mg/ml; Troy Laboratories Pty Ltd, Smith-
field, Australia) and placed in a stereotaxic apparatus (Kopf Instruments, Tujunga, California)
on the day prior to lesioning. Osmotic micro-pumps (Model 1007D; Alzet, Palo Alto, Califor-
nia) were filled with 24.5 ng/μl (294 ng total daily dose) of recombinant human/mouse/rat acti-
vin A (R&D Systems) or vehicle control (1x PBS) and implanted subcutaneously along the
back of the neck as previously described [7]. An infusion cannula (PlasticsOne, Roanoke, US)
connected to the micro-pump was placed in the left lateral ventricle (to ensure the cannula did
not impede subsequent lesioning) at AP -0.26, ML -1.0, DV -2.8 relative to bregma. The pump
was removed 1 week later and the cannula tubing sealed with heat.
Unilateral striatal lesioning
Animals were anaesthetized with a mixture of ketamine (8.7 mg/ml; Mavlab, Slack Creek,
QLD) and xylazil (2 mg/ml; Troy Laboratories Pty Ltd, Smithfield, Australia) and placed in a
stereotaxic apparatus (Kopf Instruments, Tujunga, California). Mice were then injected with
2 x 2 μl of 3 mg/mL (total 12 μg) of 6-hydroxydopamine (6-OHDA; Sigma Aldrich, Australia)
in 0.02% ascorbic acid (sham) in the right sensorimotor striatum at the following coordinates:
AP +1.0, ML +2.1, DV -2.9 and AP +0.3, ML +2.3, DV -2.9, relative to bregma and the dural
surface as previously described [8]. 6-OHDA (or 0.02% ascorbic acid control) was injected at a
rate of 0.5 μl/minute and the syringe left in place for 2 minutes after each injection to allow for
complete diffusion.
Immunohistochemistry
Mice were anaesthetized with ketamine (8.7 mg/ml; Mavlab, Slack Creek, QLD) and xylazil (2
mg/ml; Troy Laboratories Pty Ltd, Smithfield, Australia) and transcardially perfused with ice-
cold phosphate-buffered saline (PBS) and 4% paraformaldehyde (PFA) 1, 2, or 3 weeks after
lesioning. For all neuroprotection studies animals were transcardially perfused 3 weeks after
lesioning. Brains were harvested and postfixed in 4% PFA at 4°C overnight and then cryopro-
tected in 30% sucrose. Tissue was cryosectioned at 40 μm and stored in PBS with 0.02% sodium
azide at 4°C until used. For all sections endogenous peroxidases were quenched using 3% H2O2
in 50% ethanol for 20 minutes and were subjected to blocking with 3% Bovine Serum Albumin
(BSA) + 0.25% Triton in 1x PBS for 1 hour at room temperature to block all non-specific sites.
Sections were then incubated in the following primary antibodies: monoclonal mouse tyrosine
hydroxylase (TH, 1:1000 Sigma Aldrich, Australia cat # T2928), monoclonal mouse neuronal
nuclei (NeuN 1:500, Merck Millipore, Australia cat # MAB377), monoclonal rat dopamine
transporter (DAT 1:1000, Merck Millipore, Australia cat # MAB369) for 72 hours at 4°C. All
sections were then incubated in the respective biotin-labeled secondary antibodies (1:250, Sap-
phire Bioscience cat # AB6813, Life Technologies, Australia cat # B-2770, Sigma Aldrich, Aus-
tralia cat # B7139) overnight at 4°C followed by incubation in avidin-biotin complex (Vector
Laboratories, USA) at room temperature for 1 hr. TH and DAT immunolabeling was detected
with 3,3’-Diaminobenzidine (DAB, Abacus) until desired staining achieved. NeuN
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immunolabeling was detected with DAB intensified with nickel ammonium sulfate and coun-
terstained with polyclonal rabbit anti-TH (1:1000, Merck Millipore cat # AB152) that was de-
tected with Nova-Red (Abacus) to outline the substantia nigra region.
Stereology
Quantification of SNpc cell population estimates was performed using the optical fractionator
method and the use of Stereo Investigator 7 software (MBF Bioscience). For the estimations of
TH positive populations a counting frame of 60 μm x 60 μm and a grid size of 75 μm x 85 μm
was used. For the estimations of NeuN positive populations a counting frame of 65 μm x
65 μm and a grid size of 135 μm x 145 μmwas used. For all cell types the guard zone height
used was 5 μm and dissector height used was 10 μm, with every third section sampled to a total
of 10 sections. Coefficient of error attributable to the sampling was calculated according to
Gundersen and Jensen [9]. Errors0.10 were regarded as acceptable. The medial lemniscus
was used to define the border between the SNpc and VTA and the SNpc was delineated from
-2.8 to -3.88 mm relative to bregma based on the Paxinos atlas for the mouse brain [10].
Catecholamine analysis
Animals were sacrificed by cervical dislocation 3 weeks after lesioning, the brains removed and
the striatum rapidly dissected out and snap frozen. The day prior to catecholamine analysis,
the mobile phase solution consisting of 0.1 mol/L phosphate buffer (pH 3.0), 0.74 mmol/L
PIC B-8 octane sulphonic acid (Waters, Australia), 0.3 mmol/L sodium EDTA, and methanol
(18% v/v) was prepared, run through the system, and maintained at a flow rate of 0.7 mL/min
overnight. Striata were homogenized with a 1 ml solution of ice-cold 0.2M perchloric acid
containing 0.1% L-cysteine and 400 nmol/L of 5-hydroxy-N-nethyltryptamine (5-HMeT) as
internal standard. Following homogenization, 50 μl of homogenate was aliquoted for protein
analysis and placed on dry ice. The remainder of the homogenate was centrifuged at 15,000g
at 4°C for 15 min and 10 μl aliquot of the supernatant was analyzed by HPLC. The HPLC
system consisted of a Shimadzu ADVP module (Kyoto, Japan) equipped with a SIL-10 autoin-
jector with sample cooler and an LC-10 on-line vacuum degassing solvent delivery unit. Chro-
matographic control, data collection and processing were carried out using Shimadzu Class VP
data software. Dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid
(HVA), and 5-HMeT were separated by a Phenomenex Synergi Polar-RP 80A reversed phase
column with Optiguard C18 (1 mm). Quantification was achieved via an intro electrochemical
detector (Antec Leyden, Netherlands) equipped with a glassy carbon working electrode set at
+0.75V. The calibration curve of each standard was obtained by the concentration versus the
area ratio of the standard and internal standard (5-HMeT). Catecholamine levels were stan-
dardized to protein levels measured via Bradford assay and recorded as ng/μg of protein. All
standards for the Bradford assay were prepared in freshly made 0.2M PCA + 0.1% L-cysteine.
Densitometry
Optical densitometry was performed on DAT-positive fibres in the striatum using Image Pro
Plus 6.0 software (Media Cybernetics, USA). Digital images were captured on a Leica DM4000
B LED microscope at a 5x magnification using a Leica DFC 450 camera and the Leica Applica-
tion Suite V43 software (Leica Microsystems, Switzerland). All lighting conditions and magni-
fications were held constant and the investigator was unaware of the experimental groups. The
color images were converted to 8-bit greyscale images. For each animal, the average optical
density was determined at the following coordinates relative to bregma: -0.24 mm, -0.48 mm,
-0.72 mm, and -0.96 mm, measuring a total area of 1,200,000 μm2. The measured values were
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corrected for non-specific background staining by subtracting values obtained from the cortex.
The damage was calculated as the percent of the DAT-positive area in the lesioned striatum di-
vided by the DAT-positive area of the untreated contralateral side.
Statistical Analysis
All statistical analysis was performed using GraphPad Prism Version 6.0 (GraphPad Software,
Inc). Differences between means were assessed, as appropriate, by two- or one-way ANOVA
followed by Bonferroni post hoc analysis.
Results
6-OHDA induces cell death in a time-dependent manner
It has been previously shown that activin A is able to protect against 6-OHDA-induced degen-
eration in vitro [6]. To investigate if activin A exerts the same neuroprotective effect in vivo, we
first aimed to establish a time course of 6-OHDA-mediated cell death. Following unilateral in-
jection with 6-OHDA, dopaminergic and total neuron numbers were quantified using stereo-
logical analysis of TH and NeuN positive cells, respectively, at 1, 2, and 3 weeks post lesioning.
No effect of direct physical damage caused by the infusion was found, with no significant
differences in the number of TH positive cells between the unlesioned and “lesioned” sides of
the sham injected animals (S1 Fig). Furthermore, no significant differences were found be-
tween sham and 6-OHDA injected animals on the unlesioned side, demonstrating that degen-
eration is confined to the ipsilateral side (S1 Fig). Analysis of NeuN positive cell numbers of
the unlesioned side demonstrated similar results (S2 Fig).
Two-way ANOVA demonstrated a significant interaction between toxin and time on TH
positive cell numbers in the SNpc (F(2,12) = 13.10 p<0.001) indicating a significant effect of
6-OHDA on dopaminergic cell survival over time. Therefore separate one-way ANOVAs were
conducted on toxin and time. Significant loss of TH positive cell numbers was observed at 1
(t(1,4) = 2.889, p<0.05), 2 (t(1,4) = 6.641 p<0.01), and 3 weeks (t(1,4) = 19.65 p<0.001) following
unilateral 6-OHDA lesioning compared to their sham controls (Fig 1A and 1B). A one-way
ANOVA of 6-OHDA treatment indicated significant loss of TH positive cells with time
(F(2,6) = 80.30 p<0.001). A Bonferroni post-hoc analysis revealed a significant difference in TH
positive cells between 1 and 2 weeks (p<0.01), 2 and 3 weeks (p<0.01), and 1 and 3 weeks post
lesioning (p<0.001).
Two-way ANOVA of stereological quantification of total neuronal loss demonstrated a
significant interaction between toxin and time on NeuN positive cell numbers in the SNpc
(F(2,12) = 12.96 p<0.01) indicating a significant effect of 6-OHDA on neuronal cell survival
over time. Therefore separate one-way ANOVAs were conducted on toxin and time. Signifi-
cant loss of NeuN positive cell numbers was observed at 1 (t(1,4) = 4.325, p<0.05), 2 (t(1,4) =
8.384 p<0.01), and 3 weeks (t(1,4) = 11.86 p<0.001) following unilateral 6-OHDA lesion com-
pared to their sham controls (Fig 2A and 2B). A one-way ANOVA of 6-OHDA treatment indi-
cated significant loss of NeuN positive cells with time (F(2,6) = 29.7 p<0.001). A Bonferroni
post-hoc analysis revealed a significant difference in NeuN positive cells between 1 and 2 weeks
(p<0.05), 2 and 3 weeks (p<0.05), and 1 and 3 weeks post lesioning (p<0.001). The results
from this study demonstrate that unilateral 6-OHDA administration results in significant and
progressive dopaminergic and total cell loss, with the greatest degeneration present at 3 weeks
post-lesioning.
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Activin A increases survival of dopaminergic neurons against 6-OHDA-
induced toxicity
After establishing a time course of 6-OHDA-mediated cell death, in which counts at 3 weeks
post lesioning revealed the highest level of cell loss in our study, we aimed to investigate if acti-
vin A is neuroprotective against 6-OHDA-induced degeneration. We therefore quantified the
number of TH positive cells in the SNpc 3 weeks after 6-OHDA lesioning. Two-way ANOVA
Fig 1. Time-dependent dopamine cell loss induced by 6-OHDA. (A) Representative images of TH-immunoreactive neurons in the SNpc. (B) Stereological
quantification revealed a significant and progressive loss of dopaminergic cell numbers at 1, 2, and 3 weeks following unilateral injection of 6-OHDA or
ascorbic acid (sham). All values represent the mean ± standard error of the mean (SEM) *p<0.05, **p<0.01, ***p<0.001 (compared to sham controls),
##p<0.01, ###p<0.001. N = 3 per group. Scale bar represents 200 μm.
doi:10.1371/journal.pone.0124325.g001
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analysis of stereological quantification demonstrated a significant interaction between toxin
and drug treatment (F(1,20) = 9.288 p<0.01), suggesting an effect of activin A on lesion severity.
Therefore separate one-way ANOVAs of toxin and drug treatment were conducted. Sham ani-
mals receiving activin A showed no significant differences in the number of TH positive cells
compared to sham animals receiving vehicle (p = 0.2446), suggesting that activin A does not
alter baseline levels of dopamine neurons (Fig 3A and 3B). As expected, the administration of
6-OHDA significantly decreased the number of dopaminergic neurons in both animals receiv-
ing the vehicle and activin A (p<0.001 and p<0.05, respectively). However, while 6-OHDA re-
sulted in a significant decrease in TH positive cells in animals receiving activin A compared to
Fig 2. Time-dependent nigral cell loss induced by 6-OHDA. (A) Representative images of NeuN-immunoreactive neurons in the SNpc. (B) Stereological
quantification revealed a significant and progressive loss of total cell numbers at 1, 2, and 3 weeks following unilateral injection of 6-OHDA or ascorbic acid
(sham). All values represent the mean ± standard error of the mean (SEM) *p<0.05 **p<0.01, ***p<0.001 (compared to sham controls), #p<0.05,
###p<0.001. N = 3 per group. Scale bar represents 200 μm.
doi:10.1371/journal.pone.0124325.g002
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their sham controls, there was a significant difference in dopaminergic neuron numbers be-
tween vehicle and activin A groups in 6-OHDA lesioned animals (Fig 3A and 3B p<0.01), sug-
gesting a neuroprotective effect of activin A on dopaminergic cells against 6-OHDA-
induced toxicity.
Activin A increases survival of nigral neuronal populations against
6-OHDA-induced toxicity
While the use and quantification of TH as a marker for DA cell survival is a well established
practice in animals models of PD research, it is necessary to control for the loss of this pheno-
typic marker in the absence of cell death. Therefore, to ensure that the neuroprotective effect of
activin A in dopaminergic neurons against 6-OHDA-induced degeneration was not simply a
result of decreased TH expression in vehicle treated animals, we also quantified the number of
NeuN positive cells in the SNpc. Similarly to that seen with TH, two-way ANOVA
Fig 3. Activin A protects against 6-OHDA induced cell loss. (A) Experimental timeline detailing pump implantation, unilateral injection of 6-OHDA or
ascorbic acid (sham), and tissue collection. (B) Stereological quantification of TH-immunoreactive neurons in SNpc demonstrates activin A protects
dopaminergic neurons against 6-OHDA toxicity. (C) Stereological quantification of NeuN-immunoreactive neurons in SNpc demonstrates activin A protects
total neuron numbers against 6-OHDA induced toxicity. All values represent the mean ± standard error of the mean (SEM). *p<0.05, **p<0.01, ***p<0.001.
Sham + vehicle n = 4, sham + activin A n = 6, 6-OHDA + vehicle n = 7, 6-OHDA + activin A n = 7.
doi:10.1371/journal.pone.0124325.g003
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demonstrated a significant interaction between the toxin and drug treatment (F(1,20) = 13.12
p<0.01), suggesting an effect of activin A on 6-OHDA-induced cell loss. Therefore separate
one-way ANOVAs of toxin and drug treatment were conducted. Sham animals receiving acti-
vin A showed no significant differences in the number of NeuN positive cells compared to
sham animals receiving vehicle (p = 0.9286), suggesting that activin A does not alter baseline
levels of total neuron numbers in the SNpc (Fig 3C). As expected, the administration of
6-OHDA significantly decreased total neuron numbers in both animals receiving vehicle and
activin A (p<0.001 and p<0.05, respectively). However, while 6-OHDA resulted in a signifi-
cant decrease in NeuN positive cells in animals receiving activin A compared to their sham
controls, there was a significant difference in total neuron numbers between vehicle and activin
A groups in 6-OHDA lesioned animals (Fig 3C p<0.001). As expected, the percentage of
NeuN positive cells lost following 6-OHDA was very similar to that of TH positive cells from
the same treatment group. Together, these results indicate that activin A protects total neuron
numbers in the SNpc against 6-OHDA-induced toxicity.
Activin A does not alter striatal dopamine levels following 6-OHDA
The loss of dopaminergic neurons within the SN in PD results in a subsequent loss of DA in
the striatum. As we demonstrated that activin A treatment is able to protect against both dopa-
minergic and total neuron loss induced by 6-OHDA toxicity, it would be reasonable to pre-
sume that activin A treatment would also result in a concurrent protection of striatal DA levels.
We therefore quantified catecholamine levels from striatal tissue that was homogenized in so-
lution containing 100 μM 5-HMeT (internal standard) and analyses for DA, DOPA, and HVA
via HPLC coupled to an electrochemical detector was conducted. Two-way ANOVA analysis
revealed a significant effect of toxin administration (F(1,27) = 37.05 p<0.001), with both vehicle
(p<0.001) and activin A (p<0.01) treated animals displaying significantly lower striatal DA
levels compared to their sham controls. Post hoc analysis with Bonferroni corrections revealed
no significant differences in DA levels in sham animals receiving vehicle or activin A
(p>0.9999), indicating that activin A does not alter baseline levels of DA. However, in animals
lesioned with 6-OHDA, the administration of activin A did not increase striatal DA levels in
comparison to animals receiving vehicle (Fig 4A p = 0.6847), contrasting our previous neuro-
protective effect of activin A in the SNpc.
Following its release from presynaptic terminals, DA either binds to and activates the DA
receptors D1 to D5 [11], or is actively translocated from the extracellular space into presynaptic
neurons and surrounding glial cells via the dopamine transporter (DAT) where it is then either
repackaged into synaptic vesicles or degraded into its metabolites DOPAC and HVA [12]. We
therefore quantified the amount of these metabolites within the striatum to determine if they
were altered with the administration of activin A. Two-way ANOVA with post hoc Bonferroni
corrections revealed no significant differences in DOPAC or HVA levels in sham animals re-
ceiving either vehicle or activin A (DOPAC p>0.9999; HVA p>0.9999) indicating that activin
A does not alter baseline levels of these metabolites. While the administration of 6-OHDA sig-
nificantly decreased both DOPAC and HVA levels in animals receiving vehicle (DOPAC
p<0.001; HVA p<0.001) and activin A (DOPAC p<0.001; HVA p<0.01) compared to their
sham controls, there was no significant difference in striatal DOPAC (p>0.9999) or HVA
(p = 0.6829) levels in animals 6-OHDA lesioned animals receiving vehicle or activin A (Fig 4B
and 4C). Furthermore, activin A does not alter the catabolism of DA to HVA, with two-way
ANOVA analysis revealing no significant difference in the ratio of these two catecholamines
between animals receiving vehicle or activin A and lesioned with 6-OHDA (Fig 4D p>0.9999).
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Striatal dopamine transporter expression is not restored with activin A
administration
In the striatum, the dopamine transporter (DAT) plays an important role for maintaining suf-
ficient DA levels for release into the synaptic cleft, thus when striatal DAT loss reaches levels
equivalent to those seen upon presentation of locomotor symptoms, a concomitant deficit in
DA is produced [13–15]. To investigate if the inability of activin A to restore DA levels in the
striatum following 6-OHDA, despite a protection of the DA-producing cells in the SNpc, was
due to a deficit in DAT, we quantified immunohistochemical DAT expression in the striatum
via densitometry. Two-way ANOVA with post-hoc Bonferroni corrections demonstrated no
significant difference in DAT expression in sham animals receiving vehicle or activin A
(p>0.9999), indicating that activin A does not alter baseline expression of DAT. While the ad-
ministration of 6-OHDA resulted in a significant decrease of DAT expression in the striatum
(vehicle p<0.001; activin A p<0.001), animals receiving activin A exhibited similar expression
levels compared to their vehicle controls following lesioning with 6-OHDA (Fig 5A and 5B
p>0.9999) suggesting that the neuroprotective effect of activin A may be confined to the SNpc.
Discussion
Despite decades of preclinical and clinical research, the current pharmacological therapies for
PD remain ineffective in the long term and are unable to halt ongoing nigrostriatal degenera-
tion. However, the use of growth factors has received intense focus in recent years based on
their ability to promote induction, specification, survival and maturation of developing
Fig 4. Activin A does not restore striatal catecholamine in 6-OHDA lesioned animals.HPLC-ECD quantification of striatal tissue revealed no significant
effect of activin A on (A) DA, (B) DOPAC or (C) HVA levels following 6-OHDA compared to vehicle controls or the catabolism of DA to HVA (D).
Sham = ascorbic acid. All values represent the mean ± standard error of the mean (SEM). *p<0.05, **p<0.01, ***p<0.001. Sham + vehicle n = 7,
sham + activin A n = 7, 6-OHDA + vehicle n = 9, 6-OHDA + activin A n = 8.
doi:10.1371/journal.pone.0124325.g004
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neurons within the CNS. Since the discovery of GDNF in the early 90’s, it has been demonstrat-
ed that many DA neurotrophic factors are members of the TGFβ superfamily of proteins, mak-
ing this family an attractive target for therapeutic intervention in PD.
Following promising neuroprotective and neurorestorative results in animal models, nu-
merous clinical trials of growth factors in PD patients were conducted [16]. However, the re-
sults of these clinical trials proved largely disappointing, with some endpoints not met, site
delivery and retrograde transport issues, and the presence of unwanted lesions dampening re-
sults [17–21]. Despite these translational issues, optimism remains that growth factors, and in
particular those of the TGFβ superfamily, of which activin A is a member, will prove useful for
PD.
In addition to its known neuroprotective effects in the hippocampus [2,4], it has been dem-
onstrated that activin A attenuates degeneration induced by 6-OHDA [6] or MPP+ [5]
Fig 5. Activin A does not protect striatal DA terminals against 6-OHDA-induced toxicity. (A) Representative images of DAT-immunoreactive fibres in
the striatum. Arrows represent areas of loss of DAT-positive fibres. (B) Optical density analysis demonstrates that activin A does not protect against the
6-OHDA-induced reduction in DAT-positive fibres in the striatum. Sham = ascorbic acid, CTX = cortex, STR = striatum. All values represent the
mean ± standard error of the mean (SEM). ***p<0.001. N = 5 per group. Scale bar represents 200 μm.
doi:10.1371/journal.pone.0124325.g005
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administration in vitro, providing the first suggestion that activin A may exert neuroprotective
effects in midbrain neurons. We therefore hypothesized that activin A would provide the same
neuroprotective effects against 6-OHDA-induced degeneration in vivo. Unlike the MPTP
model of PD, intrastriatal injections of 6-OHDA results in a delayed and protracted degenera-
tive process, with changes in SNpc dendritic density, cell size, gene expression, and reduction
in the number of TH positive cells occurring several days after the rapid loss of DA fibres sur-
rounding the site of injection [22]. While a number of previous studies have investigated the
time course of cell loss in the SNpc following 6-OHDA, many of these experiments were per-
formed in rats [23–25] or focused on the early events of degeneration [22]. We therefore estab-
lished a time course of degeneration in drug naïve mice to determine the point at which
midbrain neuronal loss is greatest. Stereological estimations of TH and NeuN positive cells in
the SNpc demonstrated that unilateral striatal 6-OHDA administration resulted in a time-de-
pendent loss of both dopaminergic and total neuron populations, with cell loss present at 1
week and showing constant progression up to the end of the study at 3 weeks post lesioning.
These findings raise important considerations regarding the timing and delivery of thera-
peutic agents following intrastriatal administration of 6-OHDA. Indeed, numerous studies
have demonstrated that the timing and site of administration of GDNF relative to the lesion
can modulate the neuroprotective effects of the trophic factor against 6-OHDA toxicity [26–
29]. In the intrastriatal 6-OHDA lesion model, prior GDNF administration is able to almost
completely rescue the number of nigral DA cell bodies, stimulate axonal sprouting and re-
growth, and stimulate DA turnover and function. However when administered after 6-OHDA,
GDNF is unable to provide the same neuroprotective effects, with a significant DA denervation
still occurring within the striatum [28,29]. We therefore administered activin A for a full 7
days, beginning the day prior to injection of 6-OHDA, and quantified the number of remaining
TH and NeuN positive cells 3 weeks after 6-OHDA administration. Stereological analysis re-
vealed that exogenous activin A resulted in significant protection of both dopaminergic and
total neuron numbers in the SNpc against 6-OHDA toxicity. This pronounced neuroprotective
effect of intracerebroventricular activin A may result from either activin A inhibiting the initial
degenerative phase of 6-OHDA and thus preventing further cell loss, or exerting neurotrophic
effects past the time of removal of the osmotic pump.
The loss of DA producing cells within the SN of PD patients results in a subsequent loss of
DA within the striatum, and ultimately a disruption of the finely tuned signaling of the basal
ganglia. Our studies reveal that activin A can significantly increase the survival of midbrain do-
paminergic neurons following intrastriatal 6-OHDA administration and it could therefore be
hypothesized that activin A would also result in a subsequent protection of striatal DA levels.
HPLC-ECD analysis of catecholamine levels in the striatum of vehicle and activin A treated an-
imals revealed that while 6-OHDA resulted in a significant loss of striatal DA, animals receiv-
ing activin A were not significantly different from vehicle controls in DA levels or its
metabolites DOPAC and HVA. Furthermore this was not due to activin A altering the catabo-
lism of DA, with no difference in the ratio of DA to HVA found between animals receiving ve-
hicle or activin A. These results suggest that while activin A protects 6-OHDA-induced
degeneration of the DA producing nigral cell bodies, this neuroprotection does not translate to
a subsequent protection of DA levels in the striatum.
In the striatum, the dopamine transporter plays an important role for maintaining sufficient
DA levels for release into the synaptic cleft, thus when striatal DAT loss reaches levels equiva-
lent to those seen upon presentation of locomotor symptoms, a concomitant deficit in DA is
produced [13–15]. It could therefore be hypothesized that the inability of activin A to restore
DA levels, despite the increase in survival of DA producing cells, is due to the degeneration in
the striatum of the projecting fibres from the nigral cell bodies. Quantification of
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immunohistochemical DAT expression in the striatum demonstrated that activin A was unable
to protect striatal DA terminals from degeneration, with DAT expression unchanged between
vehicle and activin A treated animals following 6-OHDA. This may explain the lack of DA res-
toration and would suggest that activin A is unable to maintain striatal integrity following
6-OHDA induced toxicity.
The results of this study raise a number of intriguing questions. In particular, what is the
reason for the selective neuroprotection of the nigral cells? Numerous studies have demonstrat-
ed that the proximity to the site of lesion increases the neuroprotective effect of trophic factors
such as GDNF and Neurturin in animal models [26,30–34]. It is therefore surprising that the
neuroprotective effect of activin A appears to be confined to the cell bodies in the SNpc with no
effect on the DA terminals and DA levels, given the location of activin A administration is clos-
er to the striatum relative to the SN. It may also be the case that the site of delivery of activin A
affects its actions more generally. Alternatively, it is possible that the lack of effect of activin A
in the striatum, in our study, may result from differing direct and/or indirect actions on the
soma vs. the projecting fibres of the dopaminergic system. Furthermore, investigations in other
animal models of PD may provide the basis of determining the neuroprotective mechanisms of
activin A based on the mechanisms of degeneration of the model used. These questions raised
by our study are important not only to further investigations of activin A, but also to the inves-
tigation of growth factors in PD more generally.
With the introduction of L-Dopa as a PD therapy approximately 50 years ago, the outlook
and quality of life for patients dramatically changed, however there still remains no therapy
that treats the underlying degeneration that is characteristic of the disease. These findings pro-
vide the first evidence that exogenous activin A is able to significantly increase the survival of
midbrain dopaminergic and total neuron populations following intrastriatal
6-OHDA administration.
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S1 Fig. 6-OHDA-induced loss of dopaminergic neurons is confined to the ipsilateral side.
(A) Representative images of TH-immunoreactive neurons in the SNpc. (B) Stereological
quantification revealed no significant loss of dopaminergic cell numbers of the unlesioned
hemisphere at 1, 2, and 3 weeks in ascorbic acid (sham) animals. (C) No significant loss of do-
paminergic cell numbers was found between sham and 6-OHDA injected animals in the unle-
sioned hemisphere. All values represent the mean ± standard error of the mean (SEM). N = 3
per group. Scale bar represents 200μm.
(TIF)
S2 Fig. 6-OHDA-induced loss of total nigral neurons is confined to the ipsilateral side. (A)
Representative images of NeuN-immunoreactive neurons in the SNpc. (B) Stereological quan-
tification revealed no significant loss of total cell numbers of the unlesioned hemisphere at 1, 2,
and 3 weeks in ascorbic acid (sham) animals. (C) No significant loss of total cell numbers was
found between sham and 6-OHDA injected animals in the unlesioned hemisphere. All values
represent the mean ± standard error of the mean (SEM). N = 3 per group. Scale bar represents
200μm.
(TIF)
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